The global surgical robots market size was estimated at USD 3.92 billion in 2023 and is expected to grow at a CAGR of 9.5% from 2024 to 2030. The surgical robots market serves a multitude of applications, such as orthopedics, neurology, urology, gynecology, laparoscopy, and various others. This trend report from the GVR research team is anticipated to deliver key qualitative insights regarding the product pipelines acquired by established market players and emerging ventures.
Factors such as the growing adoption of automated surgical instruments, the rising number of knee and hip replacement surgeries due to increasing osteoporosis and arthritis cases, and the increasing preference for precise & accurate minimal invasive surgeries. For instance, according to an article published by NCBI in February 2022, around 240 million people worldwide have symptomatic osteoporosis, including 18% of women and 10% of men aged 60 and above.
Higher favorable outcomes compared to open surgeries and shorter periods of hospitalization and quicker recoveries fuel the demand for robotic-assisted surgeries, which is anticipated to boost market growth. Furthermore, technological advancements and incorporating artificial intelligence (AI) and machine learning (ML) in robotic surgeries drive market growth.
Furthermore, the global surgical robots’ market is expected to witness various changes as major healthcare players are anticipated to enter the industry. For instance, in January 2024, MassRobotics, a robotics hub that educates and brings investments, robotics initiatives, and companies along with partners Mitsubishi Electric, FESTO, MITRE, and Novanta, announced the Healthcare Robotics Startup Catalyst III Cohort to revolutionize the healthcare robotics sector.
Verticals |
Established Player |
Emerging Player |
Company Name |
Intuitive Surgical |
AcuSurgical |
Overview |
Intuitive Surgical develops, manufactures, and markets a robotic system to aid minimally invasive surgery. Globally, the company has successfully installed over 8,600 da Vinci surgical systems in hospitals worldwide, with the U.S. accounting for more than 5,000 of those installations and a growing number in emerging markets. Intuitive has over 12,100 employees and a presence in more than 60 countries. |
AcuSurgical is a France-based surgical robotics company. The company develops retinal microsurgery devices used in eye operations. The company's device is a robotic surgical assistant that aids in the treatment of retinal diseases such as age-related macular degeneration, helping surgeons increase the precision of current procedures, augment visualization, and filter tremors. |
Established Year |
1995 |
2020 |
Products |
The company has the following products,
|
|
Application |
The Da Vinci system is used in a wide range of surgeries. However, it is mostly used for gastrointestinal, urological, and gynecological surgeries. In addition, more than 70% of Da Vinci procedures are hysterectomies and prostatectomies. |
|
Partnerships in terms of technology, distribution |
salesforce American Cancer Society |
MERIEUX EQUITYPARTNERS biologie, ingeniene elimagene de la greffe de Comee |
Pipeline Product |
Da Vinci 5 |
Luca Robotic Surgery Platform |
Growth Strategies |
Intuitive Surgical invests heavily in R&D, enhancing its digital tools and platforms. The company's most significant development was submitting its 510(k) application for da Vinci 5, a next-generation multi-port platform, in 2023. |
|
The total volume of surgeries performed across different specialties using da Vinci surgical systems in the U.S. are as follows,
Verticals |
Established Player |
Emerging Player |
Company Name |
Intuitive Surgical |
AcuSurgical |
Pipeline Product |
da Vinci 5 |
Luca Robotic Surgery Platform |
Benefits |
|
|
Clinical Trials Data |
Ohio State leads the testing and trials of the new surgical robot da Vinci 5 developed by Intuitive Surgical. The trials were conducted at the Ohio State University Comprehensive Cancer Center-Arthur G. James Cancer Hospital, Richard J. Solove Research Institute (OSUCCC-James), and the Ohio State University College of Medicine. Moreover, clinical trials with patient involvement have confirmed the safety and efficacy of the da Vinci 5. In March 2024, the company received U.S. FDA approval for da Vinci 5. |
In March 2024, AcuSurgical completed its first clinical case, successfully and safely performed at Ghent University Hospital in Belgium by Dr. Fanny Nerinckx. |
GET A FREE SAMPLE
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
ESOMAR certified & member
ISO Certified
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.
"The quality of research they have done for us has been excellent..."